Gossamer Bio – $317 Million IPO
San Diego – February 21, 2019 – Cooley advised the underwriters on Gossamer Bio’s $317.4 million initial public offering of 19,837,500 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Partners Charlie Kim, Sean Clayton, David Peinsipp and Kristin VanderPas led the Cooley team advising the underwriters.
Prior to the re-opening of the SEC, the launch was scheduled to be the first healthcare IPO to pursue the creative solution of going public using an automatically effective registration statement during the government shutdown. It was also one of the largest healthcare IPOs of the last 20 years.
Bank of America Merrill Lynch, SVB Leerink, Barclays and Evercore ISI acted as joint book-running managers for the offering.
Gossamer Bio, whose securities now trade on the Nasdaq Global Select Market under the symbol “GOSS,” is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,000+ lawyers across 14 offices in the United States, China and Europe.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.